Abstract
Introduction
When a leucocyte population from peripheral blood, spleen, or lymph nodes (responder = R) is, in an in vitro mixed culture system, sensitized with leucocytes from 3On leave of absence from the Instituto di Genetic Medica, Universita di Torino, Torino, Italy.
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a donor (stimulator = S) carrying a different haplotype at its major histocompatibility complex (MHC) then, in the responder population thymus-derived lymphocytes give rise to killer cells. These are able to recognize specifically and to lyse target cells sharing an MHC haplotype with the stimulator cell. Such systems can be viewed as candidates for in vitro models of allograft rejection (for review see Cerottini and Brunner 1973) .
In studies on the genetic control of induction and effector phase of this type of cell-mediated cell lysis, the most widely used assay for cell destruction employs s iCr.labeled PHA-stimulated leucocyte populations as targets. These are exposed for not more than 4-6 hours to the putative killer cells. This particular variant of cellmediated cell lysis is called cell-mediated lympholysis (CML) (Lightbody et al. 1971) .
A number of reports from different laboratories show that in the mouse the determinants detected by the killer ceils in CML (CML-determinants) are controlled by loci very closely linked or identical with the H-2K and H-2D loci controlling the serologically def'med ubiquitous major histocompatibility antigens of this species , Abbasi et al. 1973 , Nabholz et al. 1974 ). This interpretation is based on comparison of the results obtained with different combinations of responder, stimulator, and targets (T) involving congenic and noncongenic inbred strains carrying a variety of recombinant H-2 haplotypes. The results suggest, but do not prove, that CMLdeterminants are identical with the (H-2K and H-2D) molecules that carry the classical H-2 specificities. Further evidence suggesting identity came from studies employing hyperimmune anti-H-2 sera with defined specificity (Nabholz et al. 1974) . Such sera were found to block CML only when they are directed against the H-2K or H-2D incompatibility against which the killer is active. (In particular, sera directed against immune response region associated (Ia-) antigens have no blocking activity in CML; M. Nabholz, unpublished results).
(The only findings that seem incompatible with identity of CML, with H-2K, and H-2D determinants are those o'f Edidin and Henny (1973) who found that capping with polyspecific sera probably directed mainly against H-2 antigens could remove all antigens as detected by immunofluorescence and complement mediated lysis without impairing the susceptibility of capped targets to cell-mediated lysis. Barring proof to the contrary, we feel that their data are likely to reflect different requirements of various assay systems with regard to the number of H-2 molecules on the target cell.)
If the CML loci are not identical with the H-2K and H-2D genes, then an explanation of the accumulated data requires either a) that not only the CML genes but also their products are very closely associated with H-2K and H-2D genes or products, respectively, the latter association corresponding to the coupling phase of the alleles involved; or b) that anti-H~2 sera generally contain undetected noncomplement binding blocking antibodies directed against CML determinants.
The preceding summary of the present situation illustrates the limits of the information that can be obtained from studies with genetic recombinants in a finestructure analysis of H-2. Clearly the development of strains carrying novel H-2 haplotypes derived by point mutations from a well-characterized existing haplotype could further such analysis. However, in view of our considerable ignorance of the nature and mechanisms of mutagenesis in higher organisms, it seems advisable to investigate to what extent our concepts, derived from studies in bacteria and fungi, can be extrapolated to mammals. Bailey et aL (1970) , through skin grafting, discovered in a (C57BL/6 • BALB/c)F 1 mouse a spontaneous mutation in the H-2b haplotype. The novel haplotype is designated H-2 ba and carried on a C57BL/6 (B6) background in the strain B6-C-H(zl) (short: H(zl), alternative designation B6. C-H-2aa) . The mutant and B6 show strong reciprocal skin-graft rejection, and the mutation responsible for this incompatibility could, by complementation studies, be mapped into the K end of the H-2 complex. Nevertheless, the strains could not be distinguished serologically either by H-2 typing or by repeated attempts at reciprocal immunization (Bailey et al. 1970) . Nor did a ratanti-B6 serum reveal any serological differences with H(zl) (M. Cherry and D. Bailey, personal communication) . Widmer et al. (1973) demonstrated strong bidirectional incompatibility with regard to both the mixed leucocyte reaction (MLR) and CML. This latter result, confirmed by us, presents a puzzle in that previous studies in various laboratories (Bach et al. 1972 , Meo etal. 1973a , Nabholz et al. 1974 , Abbasi et al. 1973 ) had provided strong evidence for genetic separation of CML-and MLR-determinants, a strong MLR-response being tied to incompatibiltiy within a segment of the/-region (Meo et al. 1973b ) not including H-2K. Therefore, both with regard to an understanding of mutational events in mammals, in general, as well as in the context of the fine structure analysis of the MHC, an attempt to map more precisely the mutational changes in H(zl) leading to MLR-and CML-incompatibility wi~ B6, respectively, seemed necessary. The present report contains results bearing on the location of the CML mutation in H(zl) as well as those of a study on cross-reactions between the new (private) CML specificity of H(zl)and (public) CML specificities of other H-2 haplotypes.
Materials and Methods
Mice. Animals of the strains C57BL/6J (B6) and BALB/cJ as well as the F 1 hybrids, B6 • A/J and BALB/c • B6, were obtained from the Roche animal colony in Fiillinsdorf. All other inbred strains are maintained as breeding stocks in the Human Genetics Department, Ann Arbor. For production, they are occasionally bred in the Basel Institute for Immunology. The original source of most of these strains is listed in a previous publication (Meo et al. 1973a) . Strain B6.C-H(zl) was a gift of Donald W. Bailey, The Jackson Laboratory; strain AQR was a gift of Jan Klein, present address: Department of Microbiology, The University of Texas, Southwestern Medical School, Dallas, Texas.
H-2 haplotypes of strains are indicated in terms of the allelic origins of the K,/, S, and D regions respectively.
All experimental methods have been described in detail in a previous report (Nabholz et al. 1974) . Briefly, they are as follows.
Culture Conditions.
Cells are cultured at 37~ in a humidified incubator supplied with a mixture of 95% air-5% CO2.
Media.
Culture medium is RPMI containing penicillin, streptomycin, additional glutamine, 30 mM HEPES, 3 • 10-s M 2-mercaptoethanol, and 20% fetal calf serum.
CML assays are carried out in similar medium, but without 2-mercaptoethanol and with only 10% fetal calf serum. In experiments involving the addition of antisera to killer/target mixtures, 10tal of antiserum are added to the well first, then 50/al of killer cell suspension, and last, 25/al of target cells. The microtest plate is kept on ice during the addition of ceils and sera and not spun before incubation at 37~ One hundred microliters of PBS are added before the postincubation spin. The s tCr counts in the two samples obtained from each well are determined and used to calculate percent specific release = 100 • (percent experimental release -percent spontaneous release) / (100 -percent spontaneous release) and standard deviations thereof.
Mixed Leucocyte Cultures (MLC)
Antiserum Fractionation: In one experiment ammonium sulfate precipitates of antisera were used. The precipitates had been redissolved in, and extensively dialyzed against, phosphate buffered saline.
Results

Mapping the New Private CML Specificity Characteristic of B6.C-H-2ba. a) Cross-reaction Between B6 and H(zl ). When B10.A (5R) responder cells (H-2
haplotype: bbdd) are stimulated with B6 cells, the resulting killer cells display approximately equal levels of lytic activity against B6, H(zl) or A.BY targets (the last strain shares with B10 the H-2b haplotype) (Fig. 1) . This is expected as the killer cells should be directed against the private CML specificity associated with the H-2D b region common to all three target strains. The specific lysis observed in this situation can be used as a standard to which lyric potentials of other responder/stimulator combinations on the same target cells are compared (see also Nabholz et al. 1974) . Thus when cells from strain HTG (dddb) are stimulated with B6, the resulting killer cells are much more active against B6 and A.BY than against H(zl). The reverse result is obtained when H(zl) is the stimulator of HTG. These results establish that the mutation(s) in H(zl) must have led to a change in the private K end CML specificity of B6, which, by extrapolation from the earlier described work, is controlled by the H-2Kb allele or by a gene extremely closely linked to it. b) Inhibition of CML Between B6 and H(zl) by Specific Antisera. Previous work (Nabholz et aL 1974) had demonstrated that antisera could block CML only when they were directed, presumably, against the same H-2K or H-2D determinants as the killer cells. [Anti-H-2 sera directed against the responder cells have no detectable blocking activity, (Cerottini and Brunner 1973, Nabholz et al. 1974) ]. In particular, killing directed against Kb-region CML determinants could be blocked by an anti-H-2.33 serum [(B10.D2 X A)F 1 anti-HTI]. This inhibition did not interfere with killing directed against D end determinants on the same target cells. This is true even when both killer and target cell carry the Kb region (unpublished results). The same serum was able to completely block lysis of both B6 and H(zl) targets by HTG (dddb) (Table 1) . In this study, an additional serum (a gift from S. Cullen and S. Nathenson) prepared by immunization of HTG mice with cells from a B6 thymoma cell line, EL4, which does not express detectable Ia-(immune response region associated) antigens, was used. The difference between the two sera lies in the fact that the anti-H-2.33 serum may, and probably does, contain anti-Ia antibodies (for review, see Shreffler and David 1974) , while the latter, in precipitation analysis (Cullen et al. 1974) , does not recognize Ia-specificities (S. Cullen and S. Nathenson, personal communication). It may, on the other hand, have activity against some of the public H-2Kb specificities. High concentrations of these two sera completely abrogate specific cell lysis either by appropriately sensitized H(zl) cells against B6 targets or in the reverse direction (Fig. 2a) . Sodium sulfate fractionated antisera still give very strong inhibition (Fig. 2b) . The degree of inhibition can be assessed by comparing the specific lysis obtained in the presence of antiserum to the dose-response curve resulting from variation of the killer cell number. Thus, e.g., in the experiment shown in Fig. 2b , the highest concentration of either fractionated antiserum reduces the specific release of B6 stimulated with and tested against H(zl) to the level obtained with a 1:9 dilution of the same killer, i.e., killing is inhibited by about 90%.
In both experiments inhibition by either antiserum of B6 target cell lysis is significantly stronger than inhibition in the reverse direction. The results suggest the possibility that the affinity of blocking antibodies in these sera is somewhat less for H(zl) than for B6. However, as we do not know the kinetics of inhibition with regard to antisera concentration at different concentrations of killer cells, we cannot interpret this observation with certainty. The cytotoxicity titers of the two antisera on B6 and H(zl) cells are not significantly different. Widmer et al. (1973) had reported that B6 stimulated with H(zl) was able to lyse also B10.BR (H-2k) cells to a considerable degree. Our own work hinted at the existence of cross-reactions detectable in CML (Nabholz et al. 1974) and subsequent analysis (manuscript in preparation) has revealed extensive but specific cross-reactivity in CML assays between different H-2 haplotypes, including cross-reaction between K and D end CML specificities. We have attempted to map some of the cross-reacting determinants detected by B6 when stimulated with B6.C-H(zl). The results of one particular experiment are illustrated in Fig. 3 and our findings are summarized in Table 2 .
Analysis of Cross-reaction Between the New CML-specificity of H(zl) and CMLSpecificities ofOtherH-2Haplotypes.
It is clear that B6 stimulated with H(zl) reacts significantly against all tested strains except HTG. Comparing the 1-1-2 haplotypes of HTG (dddb), HTI (bbbd), and BALB/c (dddd) it is evident that at least one cross-reacting determinant is controlled by the H-2Da region. This cross-reaction is abrogated, as expected, by complementation with either A/J or BALB/c. Furthermore, although there is significant crossreaction by B6 stimulated with H(zl) against BIO.A (2R) (kkdb), it is much weaker than against B10.A (kkdd). This suggests that part of the latter cross-reaction is against determinants controlled by the K end of the H-2a haplotype. This interpretation is supported by the fact that complementation with BALB/c reduces the crossreaction against B10.A but not against B10.A (2R). That this cross-reacting specificity is controlled by the H-2Kk region follows from the fact that it is not present on cells of the strain AQR (qkdd).
Discussion
The results reported here establish that H(zl) carries a new private CML specificity controlled by the gene determining the private K end CML specificity of B6. Thus, from the previous genetic analyses of CML, we can extrapolate that the private CML specificity characteristic for H(zl) is controlled by a locus identical or very closely linked to H-2K. +: Negative or very weak reaction. +, ++, ++++: increasing amounts of lysis (see Fig. 3 ).
This interpretation is supported by the finding that both a monospecific H-2.33 serum as well as the HTG-anti-EIA serum, can block the lyric reaction between B6 and H(zl) in either direction. Together the experiments suggest that the new private CML specificity of H(zl) is controlled by the H-2K locus itself.
Two alternative explanations cannot be ruled out: a) The CML determinants may in fact be controlled by a locus not only very closely linked to the H-2K locus but the product of which also is on the cell surface physically linked to the H-2K gene product, recognized by the antisera, b) It is conceivable that the private K end CML determinants of B6 and H(zl) are controlled by genes of the I region (as the earlier genetic analyses of CML made this very unlikely for the available haplotypes resulting from crossovers between K and I regions, this would probably mean that CML determinants can be controlled by different loci in the different haplotypes and that the anti-EIA serum contains noncomplement fixing antibodies against these determinants).
The cross-reaction analysis clearly demonstrates the existence of CML specificities shared by K and D end associated CML determinants, and that the cross-reacting specificities analysed so far map in the K and D regions themselves. The finding of K-D cross-reaction between a presumably novel CML specificity arisen by mutation and specificities controlled by existing K and D alleles suggests that such cross-reactions do not necessarily reflect the very "old" specificities that arose prior to the duplication event(s) that gave rise to the bipartite structure of H-2 (Klein and Shreffler 1970) .
If the mutation is in the H-2K locus then, not being detectable serologically, it presumably affects only a small part of the H-2 molecule. [One would then interpret the cross-reactions as an example of a "simplex-complex" situation, i.e., the crossreactions are a result of similarities between the cross-reacting specificities and the new private CML specificity of H(zl)].
In any case the alteration must be in the site determining the private CML specificity of B6 and, presumably, the specificity responsible for the strong skin-graft rejection between B6 and H(zl). Thus, if the size of the T-cell receptor combining site is comparable to that of an antibody molecule, then the results suggest that the private CML-(T cell) and the private serological (B cell) specificities are not the same molecular sites, whether they are on the same molecule or not. Alternatively, one could envisage that the structure recognized by the T cell is much larger than that recognized by an antibody and that the unchanged private B cell specificity is a part of the private T cell specificity, but the only serologically recognizable one. Whatever the view on the nature of the T-cell receptor for histocompatibility determinants, the data reported here suggest that, as for soluble antigens (Hammerling and McDevitt 1974) , T-and B-cell dictionaries for histocompatibility determinants are different.
The results reported here do not resolve the puzzle presented by the observation that B6 and H(zl) are mutually incompatible with regard to both MLR and CML, while the determinants recognized by the two tests have genetically been separated and mapped into different parts of the K end of the H-2 complex using two different recombinants between H-2K and Ir-lA , Meo et al. 1973a , Nabholz et al. 1974 , Abbasi et al. 1973 . The most plausible explanations of this apparent inconsistency are:
1. The H-2b haplotype is different from the previously analysed ones (k,s,q) with regard to the distribution of MLC genes in that the H-2Kb locus (or the CML locus associated with it) controls a strong MLR determinant. This hypothesis is supported somewhat by the finding that anotherH-2b mutant derived from B6, M505, although different from H(zl), is incompatible with B6 both in MLR and CML (see accompanying paper by Forman and Klein). Alternatively, one might argue that the private K end CML specificity of B6 is controlled by the strong MLR determinant(s) in the I region, but the evidence suggesting that in the test described here, i.e., on PHA-stimulated target cells, no determinants controlled by I region loci are detected is quite strong. (On the other hand, recent experiments have, in fact, revealed that 1 region-associated incompatibilities can be detected through skin grafting (Klein et al. 1974) and by killer cells generated in vitro when LPS-stimulated, instead of PHA-stimulated cells, are used as targets (M. Nabholz, et al. manuscript in preparation)).
2. According to the grid hypothesis (Boyse 1970 , Ceppelim, 1970 ), a change in the H-2K locus could affect the expression of MLR determinants coded for by genes in the I region. There is no evidence supporting an interaction of this type, and earlier cited genetic analyses of MLR show that it is unlikely to be operative at least in the available relevant recombinants between H-2K and Ir-1.
3. H(zl) differs from B6 not only in the H-2K but also in the I region-associated MLR-genes because of a second mutation that has occurred in the H-2ba chromosome. [No differences between B6 and H(zl)have been found in responsiveness to a number of antigens, the response to which is under Ir-1 control (McDevitt, personal communication)]. The similarities between H(zl) and M505 mentioned above would lead us to expect that the probability of such a second mutation leading to MLR incompatibility is not independent of the one detected by CML.
Further genetic analysis of the MLR incompatibility between B6 and H(zl) may help to distinguish between these alternatives, although most likely the final answer will depend on a biochemical characterization of the MHC products involved.
